Ford Motor Company vs State Street SPDR S&P Biotech ETF — how do they compare? Ford Motor Company trades at $13.98 (market cap $55.83B), while State Street SPDR S&P Biotech ETF trades at $158.17. The key difference: Ford Motor Company pays a 4.29% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Ford Motor Company nearer its low. Which is the better fit depends on your goals.
| F | XBI | |
|---|---|---|
Market Cap | $55.83B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $17.44 | $164.28 |
52-Week Low | $11.21 | $86.92 |
Enterprise Value | $187.79B | — |
Dividend Yield | 4.29% | — |
Signals from Pluang's Aura AI — not financial advice
Ford (F) trades at $13.98, up 1.38% with a bullish technical signal despite mixed fundamentals. The company reported negative net income of -$8.18B in 2025 but maintains strong operating cash flow of $21.28B. Recent news highlights Ford's new $28,350 Fathom EV truck launch for 2027, targeting affordable electric vehicles while managing EV transition costs through its profitable commercial Pro segment.
Outlook remains cautious with analyst consensus at $16.00 (43% buy ratings). Key opportunities include EV expansion and dividend stability ($0.15 quarterly), while risks involve persistent net losses, high debt levels (56.49% debt-to-asset), and competitive EV market pressures. The stock offers value with low P/E (11.84) but requires monitoring of profitability turnaround.
XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.
Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.
Trailing returns across standard periods
Latest headlines on both assets
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →